Day three of the 2019 BIO World Congress began by awarding three individuals who have had a profound impact on industrial and agricultural biotechnology. It was a fitting moment because, just like them, #BIOWC19 is bringing people, ideas, and technology together to bolster the bio-economy and…

As the debate on drug pricing continues, our elected leaders will almost certainly adopt policies that will significantly impact—for better or for worse—the lives of many patients. With that in mind, how we do we ensure patients are at the center of this discussion? It starts by recognizing some…

Tomorrow, biotech breakthroughs—such as biofuels that reduce carbon pollution, biodegradable plastics made from plants, or gene-edited crops that can withstand and mitigate the effects of climate change—will take center stage in Des Moines for the 2019 BIO World Congress on Industrial Biotechnology…

Congressman Stiver Continues Call for Sensible Patent Reform While there is consensus across Capitol Hill that patent reform legislation is badly needed, the path to achieving a broadly supported bill remains elusive. This is clearly no easy task, as legislators must curb abusive patent practices,…

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, recently testified at the second of three hearings in the Intellectual Property Subcommittee of the Senate Judiciary Committee on the subject of “The State of Patent Eligibility in America.” The hearings are looking at Section 101…

Today, June 19, kicks off The Cultivating Change Summit in Iowa. The three-day event, which is hosted by the Cultivating Change Foundation and sponsored by the Biotechnology Innovation Organization (BIO), will bring together more than 200 agriculture LGBT employees, human resources and diversity…

A new report from BIO and AUTM demonstrates to enormous return on investment that ultimately comes from public funding of early-stage basic research. The licensing of this research has significantly expanded US gross domestic product, industrial gross output, and jobs over the last 22 years.  …

In a much-anticipated move, the Securities and Exchange Commission (SEC) recently proposed a rule to revise the definition of “accelerated” and “large accelerated” filers.  The proposed rule would expand the scope of small public companies that are exempt from the auditor attestation of…

Most new medicines are developed through a process of collaborative licensing agreements or acquisition. Significant negotiations underlie multiple steps of the R&D lifetime for a medicine and potential partners often repeat within a given therapeutic focus or geographic expansion strategy…

In a recent piece for The Washington Post, author Christopher Rowland inaccurately suggested that the federal government has the power to effectively impose price controls over products that have a link to federally-funded research through its patent “march-in” rights under the Bayh-Dole…